Stimulants - Articles | CARLAT PUBLISHING

Clinical Update

Vyvanse Goes Generic: An Amphetamine Apart

November 1, 2024

David Liebers, MD. Psychiatry resident at NYU Langone, Department of Psychiatry.

Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.

Dr. Liebers and Dr. Aiken have no financial relationships with companies related to this material.

Known for lower misuse potential and a smoother effect profile, lisdexamfetamine stands out in ADHD treatment. This article explores what makes it unique among stimulants.

Expert Q&A

Update on Stimulant Use Disorder

October 1, 2024

Brian Hurley, MD, MBA, FAPA, DFASAM

Brian Hurley, MD, MBA, FAPA, DFASAM

Addiction physician; President of the American Society for Addiction Medicine; Medical Director of the Bureau of Substance Abuse Prevention and Control, Los Angeles County Department of Public Health, Los Angeles, CA.

Dr. Hurley has no financial relationships with companies related to this material.

The interview with Dr. Hurley provides crucial insights into the world of psychostimulants, their misuse, and the emerging Fourth Wave of the Overdose Epidemic. Dr. Hurley discusses everything from the differences between stimulants like methamphetamine and cocaine to the importance of harm reduction strategies and evidence-based treatments for stimulant use disorder.

Clinical Update

Overview of Stimulants

October 1, 2024

Michael Weaver, MD, FASAM and Noah Capurso, MD

Michael Weaver, MD, DFASAM. Professor and Medical Director, Center for Neurobehavioral Research on Addiction at the University of Texas Medical School, Houston, TX.

Noah Capurso, MD, MHS. Associate Professor of Psychiatry, Yale University, and Editor-in-Chief, The Carlat Addiction Treatment Report.

Drs. Weaver and Capurso have no financial relationships with companies related to this material.

This article offers an insightful overview of the pharmacology of various stimulant drugs, their potential for misuse, and the dangers they pose—especially with rising overdose rates due to contamination with fentanyl. Learn about the history, various classes of stimulants, and the treatments available for stimulant use disorder, as well as the crucial harm reduction strategies aimed at minimizing risks.

Research Update

High-Dose Stimulants in Adult ADHD

September 3, 2024

Sy Clark, MD

Sy Clark, MD. Dr. Clark has no financial relationships with companies related to this material.

Finding the right stimulant dose for adult ADHD can be tough. This study looked at how higher doses beyond FDA limits affect symptom control and side effects.

Stimulant Update with Dr. Brian Hurley

April 15, 2024

Noah Capurso, MD

In today's episode, Dr. Brian Hurley provides expert insights into the current state of stimulant use disorder, its implications across different regions, and available treatment options.

Clinical Update

Controlled Substances: Handling Red Flags

October 3, 2023

Jesse Koskey, MD.

Jesse Koskey, MD. Associate Clinical Professor, Department of Psychiatry and Behavioral Sciences, UC Davis Health.Dr. Koskey has no financial relationships with companies related to this material.

It’s a dilemma that will challenge the most seasoned psychopharmacologist: “My Adderall spilled down the sink.” We clarify how to respond in the post-lockdown landscape.

Clinical Update

Treating Irritability in Autism: Functional and Medication Approaches

April 1, 2023

Joshua Feder, MD

Joshua D. Feder, MD. Editor-in-Chief, The Carlat Child Psychiatry Report.

Dr. Feder has no financial relationships with companies related to this material.

Antipsychotics can be very effective for irritability in autism, but they are often unnecessary, and the side effects are truly problematic. Don’t be the prescriber who hears irritability in autism and immediate prescribes antipsychotics. There are usually multiple steps to try before using the FDA approved antipsychotic medications.

Expert Q&A

Recognizing and Treating Substance-Induced Psychosis

April 1, 2023

David Beckmann, MD, MPH

David Beckmann, MD, MPH.

Assistant professor of psychiatry and human behavior, Sidney Kimmel Medical College, Thomas Jefferson University. Philadelphia, PA.

Dr. Beckmann has no financial relationships with companies related to this material.

Clinical pearls on how to assess and treat substance-induced psychosis when you come across them in your clinic.

The Benzodiazepine-Stimulant Combo: What Could Go Wrong?

September 25, 2022

Chris Aiken, MD

Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Neurotoxicity, substance use disorders, even traffic accidents can arise from this controversial combination. We look at how to handle it in practice, including how to reduce the use and when the combination might be OK to continue.

ADHD: Beyond Stimulants

August 15, 2022

Chris Aiken, MD and Kellie Newsome, PMHNP

Richard Brown discusses symptoms that often get in the way of full recovery in ADHD, including dyslexia, and problems with working memory, processing speed, and executive function.